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Original Article
Prognostic Factors for Upper Tract Transitional 
Cell Carcinoma: A Retrospective Review of 
66 Patients
Keng Siang Png, Eugene K.W. Lim, Kian Tai Chong, Marto Sugiono, Sidney K.H. Yip and 
Christopher W.S. Cheng, Department of Urology, Singapore General Hospital, Singapore.
OBJECTIVE: We assessed the prognostic factors on recurrence and disease-specific survival of patients
treated for upper tract transitional cell carcinoma (TCC).
METHODS: Data on 66 patients who were treated for upper tract TCC in a single centre over a 13-year
period were analysed. Mean follow-up time was 49.2 months. Fifty-five out of 66 (83.3%) underwent
nephroureterectomy with excision of a bladder cuff. Four (6.1%) patients had nephrectomy alone while
three (4.5%) had renal-sparing surgery. Four patients did not receive surgery due to advanced age and
other comorbidities. Age, sex, tumour location, stage and grade were analysed as prognostic factors for
disease recurrence and disease-specific survival using log rank univariate analysis.
RESULTS: Disease recurrence occurred in 45 (68.2%) patients at a median time of 11.0 months.
Recurrences were found in the bladder in 27.3%, the contralateral renal pelvis in 4.5%, local retroperitoneum
in 19.7%, distant sites in 13.6%, with simultaneous local and distant metastases occurring in 3.0%.
Tumour stage was the only significant prognostic factor for recurrence. Presence of extraurothelial recurrence,
stage and grade were significant prognostic factors for disease-specific survival.
CONCLUSION: Tumour stage was the most consistent predictor of both disease recurrence and 
survival. These findings would guide the need for any adjuvant chemoradiotherapy. [Asian J Surg
2008;31(1):20–4]
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Introduction
Upper tract transitional cell carcinoma (TCC) is a relatively
uncommon urological cancer. Renal pelvis TCC accounts
for approximately 10% of all renal tumours and about 5%
of all urothelial tumours.1 Ureteric tumours are even less
common, with one fourth the incidence of renal pelvis
tumours.2 This study reviewed the clinical presentation,
evaluation and treatment outcomes. We aimed to identify
the significant prognostic factors for recurrence and 
disease-specific survival in patients treated in one centre
with prolonged follow-up.
Patients and methods
Patient characteristics
A retrospective review of patients treated for upper tract
TCC at Singapore General Hospital from January 1990 to
October 2002 was conducted. Sixty-six patients were iden-
tified using surgical logs and histopathology records.
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Clinical data and recurrence status were obtained by
review of all pertinent medical records up to May 2005.
Preoperative investigations performed
Intravenous urogram (IVU), computed tomography (CT)
scan, retrograde pyelogram (RPG) and rigid/flexible
ureterorenoscopy (URS) with or without biopsy were used
for preoperative diagnosis. Most patients had more than
one modality of investigation. IVU and CT scan were done
in 49 (74.2%) and 50 (75.8%) patients, respectively. RPG
and URS were done in 27 (40.9%) and 29 (43.9%) patients,
respectively.
Treatment modalities
Sixty-two patients underwent some form of operative
treatment. Nephroureterectomy with removal of a bladder
cuff was the most frequently performed procedure,
accounting for 55 (83.3%) cases. Out of these 55 patients, 41
underwent open surgery while 14 underwent laparoscopic
surgery. Four (6.1%) patients underwent nephrectomy.
Another three (4.5%) patients underwent renal-sparing
procedures because of serious comorbidities, distal ureteric
tumour location or impaired renal function. The remain-
ing four patients did not receive any definitive surgery
due to advanced age or significant medical comorbidities.
Six patients received adjuvant radiotherapy: one had
T3 disease with positive lymph nodes; two had T3 disease
with positive resection margins (at the ureteric and bladder
cuff resection lines); and three had T4 disease. Five patients
received adjuvant chemotherapy: two had T3/T4 tumours;
two had T3 tumours with positive lymph nodes; and one
had T3 tumour, positive lymph nodes and positive bladder
cuff resection margin. One patient received both adjuvant
chemotherapy and radiotherapy for T4 disease and positive
lymph nodes with positive ureteric resection margin.
Grade and stage distribution
The pathological stage and grade were available for 65
patients. Six (9.2%) patients had grade 1 disease, 27 (41.5%)
had grade 2 disease, and 32 (49.2%) had grade 3 disease.
Seven patients (10.8%) had Ta disease, 15 (23.1%) had 
T1 disease, eight (12.3%) had T2 disease, 26 (40%) had 
T3 disease, and nine (13.8%) had T4 disease. A statistically
significant correlation was evident when comparing dis-
ease grade (grades 1 and 2 vs. grade 3) and stage (Ta and
T1 vs. T2, T3 and T4): low-stage disease corresponded with
low grade, while high-stage disease had predominantly
high-grade disease (Fisher’s exact test, p = 0.001). None of
those with pTa, pT1 or pT2 primary tumours had nodal or
distant metastatic disease either at presentation or during
follow-up. Of the 15 (22.7%) patients with nodal or metasta-
tic disease, 10 had pT3 tumours and five had pT4 tumours.
Statistical method
Survival analysis was performed to assess the predictive
value of prognostic factors including age (greater vs. less
than/equal to the population mean of 69), sex (male vs.
female), tumour location (renal pelvis vs. ureter), tumour
grade (1 vs. 2 vs. 3) and stage (Ta vs. T1 vs. T2 vs. T3 vs. T4)
with regard to disease recurrence and disease-specific 
survival. In addition, the impact of urothelial versus
extraurothelial recurrence on disease-specific survival was
also compared. The American Joint Committee on Cancer
TNM stage classification was used.3 Data were entered
into a statistical database (SPSS version 13.0; SPSS Inc.,
Chicago, IL, USA) and subjected to univariate survival
analysis. Kaplan-Meier curves were created and compared
using the log rank test.
Results
Patient characteristics and clinical features are outlined
in Table 1. The male to female ratio was 2:1. Most patients
were in their sixth and seventh decades of life at diagnosis.
Eighty-two percent of patients had gross haematuria at
presentation. A prior history of bladder TCC was noted in
six (9.1%) patients. Nine (13.6%) patients had synchronous
bladder TCC when the upper tract tumour was diagnosed.
All were unilateral at presentation. Median follow-up 
of these patients was 35.3 months (mean, 49.2 months;
range, 1–158.5 months).
Of the 12 patients who received chemotherapy and/or
radiotherapy, overall outcome was poor. Eight of them
died of the disease with a median survival of 20.0 months.
Ten patients had recurrence with a median time to recur-
rence of 3.6 months.
Recurrence
Disease recurrence occurred in 45 (68.2%) patients (Table 2).
The median time to recurrence was 11.0 months (range,
1–117.0 months). The most common site was the bladder,
accounting for 18 (27.3%) cases. Three (4.5%) cases recurred
in the contralateral renal pelvis. Thirteen (19.7%) patients
had local recurrences in the retroperitoneum, occurring
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at a median time of 10.1 months. Metastatic recurrences
developed in nine (13.6%) patients at a median time of 
3.9 months. In two (3.0%) patients, there were both local
and metastatic recurrences. On log rank univariate analysis
of possible prognostic factors, tumour stage was the only
significant prognostic factor for recurrence (p < 0.001).
The Kaplan-Meier recurrence-free survival curve by tumour
stage is shown in Figure 1.
Survival
Overall median disease-specific survival was 87.0 months.
On univariate log rank analysis, tumour stage (p < 0.001)
and grade (p < 0.001) were both significant prognostic 
factors for disease-specific survival. Figure 2 shows the
Kaplan-Meier disease-specific survival curves by tumour
stage.
In addition, we compared the significance of urothelial
recurrences (bladder and contralateral renal pelvis) with
extraurothelial recurrences (local retroperitoneum or
metastatic) on disease-specific survival. There was a sig-
nificant difference in survival (p<0.001). Of the 21 patients
whose recurrences were found in urothelium, the mean
disease-specific survival was 114.8 months. Of the 24
patients who had extraurothelial recurrences, the mean
disease-specific survival was significantly worse at 55.2
months.
Table 1. Characteristics of 66 patients with upper tract transitional
cell carcinoma (TCC)
n (%)
Sex
Male 44 (66.7)
Female 22 (33.3)
Mean age, yr (range) 69 (33–92)
Presenting complaints*
Macroscopic haematuria 54 (81.8)
Loin pain 6 (9.1)
Palpable mass 5 (7.6)
Incidental diagnosis on imaging 4 (6.1)
Microscopic haematuria 3 (4.5)
Surveillance for previous bladder TCC 3 (4.5)
Side
Right 34 (51.5)
Left 32 (48.5)
Primary tumour location
Renal pelvis 34 (51.5)
Upper- and mid-ureter 9 (13.6)
Lower third ureter 17 (25.8)
Renal pelvis and ureter 6 (9.1)
Prior history of bladder TCC 6 (9.1)
Synchronous bladder TCC 9 (13.6)
*Some patients presented with more than one complaint.
Table 2. Sites of tumour recurrence over a mean follow-up of 
35 months in 66 patients
n (%)
Bladder 18 (27.3)
Local retroperitoneum 13 (19.7)
Metastases 9 (13.6)
Contralateral renal pelvis 3 (4.5)
Both local and metastatic recurrences 2 (3.0)
Total recurrences 45 (68.2)
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Figure 1. Recurrence-free survival by T stage.
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Figure 2. Disease-specific survival by T stage.
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Discussion
We reviewed our experience with upper tract TCC to assess
the effect of prognostic factors on disease recurrence and
survival. We then compared our results with similar 
retrospective studies of patients with this uncommon
urological malignancy.
With regard to patient and tumour characteristics, we
noted that these had remained relatively constant when
compared to studies in the last 20 years.4–6 In our series,
the renal pelvis remained the commonest site of occur-
rence of the primary tumour (51%). The bladder was the
commonest site of first recurrence after an upper tract
urothelial carcinoma, occurring in 40% of patients with
recurrence. The longest time to recurrence in the bladder
occurred as late as 57 months. These important disease
characteristics continue to provide valuable insight during
diagnostic and follow-up evaluations. In particular, the
high incidence of bladder recurrence mandates long-term
endoscopic bladder surveillance.
The overall outcome of the 12 patients who received
adjuvant chemotherapy and/or radiotherapy was poor.
This underlines the well-known fact that adequate surgery
remains the best hope for curative treatment in patients
with localized disease. As many as 40% and 14% of our
patients had T3 and T4 disease, respectively, and 50% had
grade 3 disease. Since T stage and grade have been repeatedly
shown to be significant prognostic factors for upper tract
TCC, it can be predicted that as many as half of our patients
will develop early recurrence or have poor survival despite
surgery. It is therefore our institution’s practice to discuss
these patients at multidisciplinary tumour conferences in
the hope of offering them some form of adjuvant treatment
post-nephroureterectomy.
In this series, local recurrence was quite high (19.7%).
Analysis of these 13 patients revealed that seven had
T3/T4 disease, four had node-positive disease and 12 had
grade 2 or 3 disease. Only one patient received adjuvant
treatment after nephroureterectomy in the form of radio-
therapy. After diagnosis of local recurrences, two patients
underwent palliative bypass surgery for symptoms of
bowel obstruction. Only one received further palliative
radiotherapy. The remaining 10 patients did not receive
further palliative treatment. The prognosis is dismal for
these patients and the benefits of any palliative treatment
should be seriously weighed against its side effects. We
therefore reserve treatment only to palliate symptoms
(such as bowel bypass surgery). Most of these patients
would receive best supportive care.
Nine of our patients had T4 tumours. Seven of them
had symptoms of gross haematuria and loin pain. Six of
them underwent nephroureterectomy and the remaining
patient had simple nephrectomy for palliation of their
symptoms. Operative treatment for such locally advanced
disease is usually non-curative. However, cytoreductive
surgery in the presence of symptoms still offers the best
form of palliation to the patient.
Surgery had been the mainstay of treatment for local-
ized upper tract TCC and this was traditionally treated by
radical nephroureterectomy with bladder cuff excision.7
High recurrence rates had been noted when a less extensive
operation was performed, particularly with more proximally
located lesions.8 These localized resection procedures
may, however, be appropriate for patients with solitary
kidney, impaired renal function or prohibitive operative
risk. Unfortunately, we could not analyse the impact of
these conservative forms of surgery on survival as only
three patients in this series underwent renal-sparing 
procedures (1 patient underwent ureteric resection with
re-implantation, 2 patients underwent ureteroscopic
resection). However, this limitation may be mitigated by
the well-known fact that tumour grade and stage are more
important to patient outcome than the type of surgery.9,10
Localized resection techniques are also acceptable for
patients with TCC of the distal ureters. Distal ureteric
tumours accounted for 25% of patients in this series, second
only to renal pelvic tumours. Renal-sparing surgery is 
preferred in patients with distal ureteric TCC which are
low-grade, low-stage tumours.5,8,11 Distal ureteric tumours
tend to be smaller and less frequently invasive than their
renal pelvic counterparts.12 Many authors had therefore
agreed that segmental ureterectomy and ureteral re-
implantation is an acceptable treatment for urothelial
tumours of the distal ureter.13–15
The benefits of laparoscopic techniques for nephrectomy
are well-described16,17 but beyond the scope of this study.
However, it is worth noting that 14 patients in this series
underwent laparoscopic surgery. This highlights the
increasing role played by minimally-invasive techniques
in upper tract TCC and renal tumours in general.18 The
recurrence rate appeared to be similar to conventional
open surgery series.19
None of the quoted series studied the impact of
extraurothelial recurrence. This study showed that
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extraurothelial recurrence in the form of local retroperi-
toneal and distant metastatic deposits adversely affected
survival. Whilst urothelial recurrence, most commonly
found in the bladder, can be detected by cystoscopy,
extraurothelial recurrence would require surveillance
imaging. Regular radiological imaging must therefore be
part of the routine follow-up surveillance of patients,
especially those with higher-stage disease.
In a series of 252 patients, Hall et al reported that
tumour stage and type of surgical procedure performed
were the only significant predictors of tumour recurrence
while stage and age were significant predictors of survival.6
Badalament et al reviewed 50 patients and found, on both
univariate and multivariate analyses, that stage was the
only significant predictor of survival.20 Likewise, Cozad
et al reviewed 94 patients with upper tract TCC and found
that stage and age were the only significant predictors of
survival on multivariate analyses.21 In our series, univariate
analysis showed that tumour stage was a significant pre-
dictor of recurrence whereas extraurothelial recurrence,
stage and grade were significant predictors of disease-
specific survival. From these series, which number more
than 50 patients each, it is apparent that tumour stage is
the only consistent prognostic factor of both recurrence
and survival. This would allow more definite application
of appropriate adjuvant therapies for patients based 
on the initial histological staging. Higher-stage disease
should also be followed-up more closely due to the higher
rate of recurrences.
This series of 66 patients studied the prognostic sig-
nificance of age, sex, tumour location, extraurothelial
recurrence, grade and stage. In reported series with more
than 50 patients, tumour stage was shown to be the most
consistent predictor of tumour recurrence and survival.
Our results reinforce this finding and will help to guide
adjuvant therapies and decisions regarding follow-up
period for these patients.
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